Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close change Change (%) Open High Low

VirBiotechnology news

Latest news

Show more
Tommy Yap 2025 Aug 09, 21:00

Week Ahead: RBA interest rate decision and US CPI data in focus

Forex Indices
Sophia Claire 2025 Aug 09, 02:20

Market Review: Gold, Oil, Geopolitics & Tariffs - A Comprehensive Overview

Ava Grace 2025 Aug 08, 15:20

Bitcoin Cycle Shift: A Look at the New Era of Institutional Dynamics & Regulation

Emma Rose 2025 Aug 08, 15:20

US and Russia Negotiating Ukraine Peace Deal: Will Conflict Be Frozen?

Noah Lee 2025 Aug 08, 13:20

Gold Futures Soar Amid Tariff Concerns: A Comprehensive Analysis

Emma Rose 2025 Aug 08, 10:20

Oil Price Stabilization: Impact of US Sanctions & Geopolitical Tensions

Ava Grace 2025 Aug 08, 08:20

Economists Warn Trump's BLS Firing Parallels Authoritarian Leaders

Ava Grace 2025 Aug 08, 06:05

Cambodia Nominates Trump for Nobel Peace Prize Over Thailand Border Conflict

Info

Spread

0.03

Spread (%)

0.6912 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Monday

13:31 - 19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

597338816

Shares Outstanding

138916000

Earnings Date (Next)

0000-00-00

instr__dividend_date

instr__ex_dividend_date

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

EPS

-4.01

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Trustpilot